Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen ...

Viridian Therapeutics stock popped Monday after the biotech company scored a win in thyroid eye disease, a condition that causes the eyes to swell. Please watch the video at Investors.com - How To ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...

(RTTNews) - Viridian Therapeutics (VRDN) Monday has granted 113,200 stock options to nine new employees and 310,700 stock options to newly appointed Chief Medical Officer, Dr. Radhika Tripuraneni.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Viridian Therapeutics Inc (Symbol: VRDN) entered into oversold territory, hitting an RSI ...